1616 East Lake Avenue
Seattle WA 98102
Ikaria Inc.
Ikaria is developing technology that triggers a natural hibernation-like mechanism that drastically lowers cells' metabolism and thus their need for oxygen. The company believes that inducing hibernation could buy time for blood-deprived tissues and minimize damage in cardiac surgery, strokes, heart attacks, and organ transplants.
More from Archive
• By
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
• By
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
• By
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
• By
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
More from Scrip
• By
While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.
• By
The first twice-yearly option for HIV prevention has been approved by the US Food and Drug Administration in an advance that “brings us closer than ever to ending the HIV epidemic,” said CEO Daniel O’Day.
• By
Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.